Evolus (EOLS) Investor Presentation - Slideshow

Product & Clinical - Jeuveau® is a 900 kDa aesthetic neurotoxin launched in the U S in May 2019, the first since Botox Cosmetic[6] - Clinical trials included over 2,100 subjects[8] - In a Phase III trial in Europe & Canada, 872% of Jeuveau® recipients were responders compared to 828% for Botox, based on Investigator Assessment of Glabellar Line Scale (GLS) improvement at Day 30[9] - In the Canada and Europe Phase III trial, the adverse event rate for Jeuveau was 376% compared to 419% for OnabotulinumtoxinA (Botox)[18] Market & Strategy - The aesthetic neurotoxins market in the USA is projected to reach $17 billion in 2021[5] - Evolus aims for Jeuveau® to achieve the 2 unit market share position in the U S within 24 months of launch[6] - A survey of 29,000 consumers showed 26% of new patients were previous users of other toxins and 23% were toxin naive[13] Financial Performance - Jeuveau® net revenue was $23 million in Q2 2019 and $132 million in Q3 2019[15] - Gross margin was 71% in Q2 2019 and 72% in Q3 2019[15] - Non-GAAP operating expense was $329 million in Q2 2019 and $291 million in Q3 2019[15]